New radiotherapy approach for advanced lung cancer
HERAN-Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
This study is testing a new type of radiotherapy for patients with advanced lung cancer who can't have regular treatment to see if it can help them live longer and feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 151 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Danish Lung Cancer Group Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Aarhus) |
| Trial ID | NCT03742687 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates a novel treatment method called heterogeneously hypofractionated radiotherapy for patients with locally advanced non-small cell lung cancer (NSCLC) who cannot undergo standard chemoradiotherapy. The study aims to assess both the effectiveness and safety of this treatment option, which is designed to minimize damage to healthy tissue while providing adequate control of the cancer. Patients are categorized based on their ability to tolerate standard treatment, allowing for a tailored approach to their care. The goal is to improve survival rates and quality of life for these patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed, inoperable locally advanced NSCLC and a performance status of 0-2.
Not a fit: Patients with uncontrolled metastatic disease or other active malignancies are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a viable alternative for patients with advanced lung cancer who currently have limited options.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving treatment outcomes for patients with advanced lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytological confirmed locally advanced, inoperable NSCLC. * Age ≥18 years. * Signed informed consent. * Performance status 0-2. * Able to comply with study and follow-up procedures. * Fertile women must have a negative pregnancy test. Fertile men and women must use effective contraception. Fertile women included in the study must use the pill, spiral, depot injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch for the duration of study treatment and one month thereafter. Exclusion Criteria: * Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields. * Dose plan conforming to protocol planning criteria not possible. * Uncontrolled metastatic disease. * Other active malignant disease.
Where this trial is running
Aarhus
- Aarhus University Hospital — Aarhus, Denmark (Recruiting)
Study contacts
- Principal investigator: Azza A Khalil, MD, PhD — Aarhus University Hospital
- Study coordinator: Azza A Khalil, MD, PhD
- Email: azzakhal@rm.dk
- Phone: +4578462556
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.